Mediterranean diet may halt prostate cancer progression, Finds study

Written By :  Dr. Nandita Mohan
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-02-05 01:00 GMT   |   Update On 2021-02-05 06:11 GMT

According to recent research, it has been found out that the Mediterranean diet is associated with a lower risk of Gleason grade group progression in men on active surveillance, as published in the American Cancer Society Journal.The Mediterranean diet (MD) may be beneficial for men with localized prostate cancer (PCa) on active surveillance (AS) because of...

Login or Register to read the full article

According to recent research, it has been found out that the Mediterranean diet is associated with a lower risk of Gleason grade group progression in men on active surveillance, as published in the American Cancer Society Journal.

The Mediterranean diet (MD) may be beneficial for men with localized prostate cancer (PCa) on active surveillance (AS) because of its anti‐inflammatory, antilipidemic, and chemopreventive properties.

Hence, Justin R. Gregg and associates from the Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas conducted this study to prospectively investigate the adherence to the MD with Gleason score progression and explored associations by diabetes status, statin use, and other factors.

The authors assessed a total of 410 men with newly diagnosed PCa on an AS protocol and the MD score was calculated across 9 energy‐adjusted food groups. Cox proportional hazards models were fit to evaluate multivariable‐adjusted associations of the MD score with progression‐free survival; progression was defined as an increase in the Gleason grade group (GG) score over a biennial monitoring regimen. In this cohort, 15% of the men were diabetic, 44% of the men used statins, and 76 men progressed

The key findings were-

a. Higher adherence to the MD was associated with a lower risk of GG progression among all men (hazard ratio [HR] per 1‐unit increase in MD score, 0.88; 95% confidence interval [CI], 0.77‐1.01), non‐White men (HR per 1‐unit increase in MD score, 0.64; 95% CI, 0.45‐0.92; P for interaction = .07), and men without diabetes (HR per 1‐unit increase in MD score, 0.82; 95% CI, 0.71‐0.96; P for interaction = .03).

b. When joint effects of the MD score and statin use were examined, a similar risk reduction was observed among men with high MD scores who did not use statins in comparison with men with low/moderate MD scores with no statin use.

Therefore, the authors concluded that "The MD is associated with a lower risk of GG progression in men on AS, and this is consistent with prior reports about the MD and reduced cancer morbidity and mortality."


Tags:    
Article Source : American Cancer Society Journal

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News